DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for sclerosteosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSclerosteosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for sclerosteosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
LDL receptor related protein 4 (LRP4) — LRP4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8S9P · 3.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Sclerosteosis is a rare autosomal recessive disorder of bone modelling, caused by loss-of-function mutations in the SOST gene that codes for sclerostin. A 1998 report described a black Senegalese man with the full features of the disease: tall stature, syndactyly, nail dysplasia, massive sclerosis of the long bones, ribs, pelvis and skull, and multiple cranial nerve involvement including optic atrophy, facial palsy and trigeminal neuralgia. This was the first case in a black African individual with no known Dutch ancestry. A 2015 study of two Egyptian brothers born to consanguineous parents identified a novel homozygous frameshift mutation — a single cytosine insertion in the SOST gene leading to a premature stop codon and loss of functional sclerostin. Their unaffected parents were heterozygous for the same mutation. A 2019 case of a 26-year-old Bangladeshi male was initially misdiagnosed as osteopetrosis but corrected to sclerosteosis based on specific clinical features.
No treatment or intervention is described in any of these three reports. All are single-case or small-family descriptions that document the clinical and genetic features of sclerosteosis in populations where it had not previously been reported. No data on survival, response rates, or sample sizes beyond the individuals described are provided. The 2019 case notes only that the patient was managed by a multidisciplinary team approach, without specifying any drug or surgical outcome.
What is still missing is any clinical trial testing a therapeutic agent, any systematic collection of long-term outcomes, and any patient stratification beyond the presence of SOST mutations. No drug is mentioned in any of these abstracts, and no claim of efficacy can be made. The natural history of sclerosteosis outside the Afrikaner population remains poorly characterised, and no funding for interventional studies is evident from these reports.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 1998 · 28 citations
Sclerosteosis: report of a case in a black African man
AbstractSclerosteosis is a rare genetic disorder of bone modelling, similar to, but distinct from, van Buchem disease; it has been described almost exclusively in Afrikaners of South Africa, a white population of Dutch ancestry. Isolated cases have been reported in a girl in Japan, a boy in Spain, and in multiracial families in Brazil and USA. Here we report a case of sclerosteosis in a black man born in Senegal. He presented with the full features of the disease: tall stature; syndactyly: nail dysplasia; massive sclerosis of the long tubular bones, the ribs, the pelvis and the skull; multiple cranial nerve involvement: optic atrophy, facial palsy and trigeminal neuralgia. Radiologic examination, visual and brainstem auditory evoked potentials, computerized tomography and magnetic resonance imaging of the skull were performed. This seems to be the first case of the disease in a black African individual, with no known relationship with Dutch ancestry.
BioMed Research International · 2015 · 11 citations · open access
A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis
AbstractSclerosteosis is a rare autosomal recessive condition characterized by increased bone density. Mutations in SOST gene coding for sclerostin are linked to sclerosteosis. Two Egyptian brothers with sclerosteosis and their apparently normal consanguineous parents were included in this study. Clinical evaluation and genomic sequencing of the SOST gene were performed followed by in silico analysis of the resulting variation. A novel homozygous frameshift mutation in the SOST gene, characterized as one nucleotide cytosine insertion that led to premature stop codon and loss of functional sclerostin, was identified in the two affected brothers. Their parents were heterozygous for the same mutation. To our knowledge this is the first Egyptian study of sclerosteosis and SOST gene causing mutation.
Series of Endocrinology Diabetes and Metabolism · 2019 · 0 citations · open access
Sclerosteosis: A Rare, Sclerosing Bone Dysplasia in a Bangladeshi Male
AbstractWe report a 26-year-old male who was initially diagnosed as osteopetrosis and referred for endocrine evaluations. But due to specific clinical features supported by investigations, we diagnosed the case as sclerosteosis. The patient was managed by a multidisciplinary team approach. Sclerosteosis may be erroneously diagnosed as osteopetrosis. However, many unique features make it a separate entity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
